Skip to main content

Corvus Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CRVS$11.35+7.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

PART I — FINANCIAL INFORMATION
​​​​
Item 1.​ ​ ​Financial Statements (unaudited)3
​​Condensed Consolidated Balance Sheets3
​​Condensed Consolidated Statements of Operations and Comprehensive Loss4
​​Condensed Consolidated Statements of Changes in Stockholders’ Equity5
​​Condensed Consolidated Statements of Cash Flows6
​​Notes to Condensed Consolidated Financial Statements7
Item 2.​Management’s Discussion and Analysis of Financial Condition and Results of Operations22
Item 3.​Quantitative and Qualitative Disclosures About Market Risk40
Item 4.​Controls and Procedures40
​​​​
PART II — OTHER INFORMATION
​​​​
Item 1.​Legal Proceedings42
Item 1A.​Risk Factors42
Item 2.​Unregistered Sales of Equity Securities and Use of Proceeds88
Item 3.​Defaults Upon Senior Securities88
Item 4.​Mine Safety Disclosures88
Item 5.​Other Information88
Item 6.​Exhibits89
​​​​
SIGNATURES90
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.